Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Acquiring LC Firm Michrom

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker today announced an agreement to acquire liquid chromatography firm Michrom Bioresources for an undisclosed amount.

Michrom, based in Auburn, Calif., provides LC instruments, accessories, and consumables to the life science, chemical, and applied markets.

Bruker said it plans to retain all of Michrom's employees. Kerry Nugent, the founder and president of Michrom, will become senior vice president of liquid chromatography at Bruker.

The deal is expected to close in a few weeks. In 2010, Michrom generated approximately $3 million in revenues.

Collin D'Silva, president of Bruker's Chemical and Applied Markets division, said that Michrom's offerings are "highly complementary" to his firm's mass spec products, and noted that Michrom's recently launched Advance nanoflow UHPLC platform and CaptiveSpray Ionization sources "will provide our customers with significant gains in throughput, sensitivity, and robustness for proteomics and other nano and capillary flow LC-MS applications."

With the deal, Bruker becomes the latest company with a significant mass spec business to acquire a complementary LC business. A year ago, AB Sciex purchased the LC business of Eksigent, and Thermo Fisher Scientific is the process of buying chromatography company Dionex.

Yesterday, Bruker announced that revenues for its fourth quarter climbed 14 percent.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.